Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
Objective: Covered stents are an important tool in managing femoropopliteal peripheral arterial disease. However, their performance is impaired by edge neointimal hyperplasia and restenosis. We examined the effectiveness of prophylactic deployment of paclitaxel-eluting stents to prevent edge resteno...
Guardado en:
Autores principales: | Rory Marples, MBBS, Matthew Binks, MBBS, Roberto Spina, MBBS, MSc, MPH, FRACP, Melissa Wright, MD, Ravi Huilgol, MBBS, FRACS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/151040d0d3a44a95b7e70b56e61a2849 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
por: Ikushima I, et al.
Publicado: (2011) -
Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery – focus on the paclitaxel eluting stent
por: Litsky J, et al.
Publicado: (2014) -
Head-to-head comparison of sirolimus-eluting stents versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of 76 studies.
por: Xinlin Zhang, et al.
Publicado: (2014) -
Everolimus-eluting coronary stents
por: Alejandro Saez, et al.
Publicado: (2010) -
Saphenous Vein Graft Aneurysm after Drug-Eluting Stent Implantation: Treatment by Covered Stent
por: Kyriacos Papadopoulos, et al.
Publicado: (2021)